



ev3 CORPORATE FACT SHEET – FOR USE ANYTIME

Contact: Julie Tracy
Sr. Vice President, Chief Communications Officer
ev3 Inc.
9600 54th Avenue North
Plymouth, MN 55442
(949) 680-1375
jtracy@ev3.net

Overview: Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. Our products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. We offer a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons.

Mission: Through talented and motivated employees, a commitment to rapid innovation, a global perspective and a personal touch, we work in close collaboration to delight our customers by delivering high quality products and services. We support and develop highly motivated, passionate, and accountable employees creating meaningful careers in a high performance environment. We adhere to quality performance principles and practices in all that we do. We do this to generate profits and returns for our shareholders that exceed comparable investments allowing us to strive everyday to help endovascular and neurovascular specialists improve patients' lives around the world.

History: ev3, Inc (Nasdaq: EVVV) was founded in 2000 to develop and market technologies for treating a wide range of vascular diseases and disorders. ev3 made several acquisitions from 2000 to 2007, including the acquisition of Micro Therapeutics in 2006 and FoxHollow Technologies, Inc. in 2007. In June 2005, ev3 became a public company with a successful initial public offering (IPO) of 11,765,000 shares offered at \$14.00 per share.

Today ev3 is the leading global medical device company focused on catheter-based technologies for the endovascular treatment of peripheral vascular and neurovascular diseases and disorders. Our corporate strategy is to be a global provider of products for underserved and emerging opportunities within the peripheral vascular and neurovascular markets by providing a portfolio of products that address a broad spectrum of physician needs and clinical indications. Our product portfolio includes a broad spectrum of over 100 products consisting of over 1,000 SKUs to treat vascular disease in the peripheral vascular and neurovascular markets, including stents, atherectomy and thrombectomy products, PTA balloons, embolic protection devices, infusion catheters/wires, embolic coils and liquid embolics.

Milestones:

February 2001	Company Founded
June 2001	MicroVena Acquired
January 2002	MitraLife Acquired, Micro Therapeutics (MTI) Distribution Agreement, European Commercial Operations Launched
March 2002	EndiCOR Acquired
August 2002	Appriva Medical Acquired
October 2002	Dendron Acquired
November 2002	Intra-Therapeutics Acquired, New U.S. Headquarters Opened
February 2003	Japan Commercial Operations Launched
September 2003	ev3 and MTI Affiliated Through Common Ownership
June 2005	Initial Public Offering (IPO) – Nasdaq: EVVV
January 2006	ev3 Completes Acquisition of Public Minority Stake In MTI
October 2007	ev3 Completes Acquisition of FoxHollow Technologies

**Executive
Team:**

Robert J. Palmisano, President and Chief Executive Officer
Shawn T. McCormick, Senior Vice President, Chief Financial Officer
Stacy Enxing Seng, Executive Vice President and President, U.S. Peripheral Vascular
Pascal E. R. Girin, Executive Vice President and President, Worldwide Neurovascular
and International
Kevin M. Klemz, Senior Vice President, Secretary and Chief Legal Officer
Gregory Morrison, Senior Vice President, Human Resources
David H. Mowry, Senior Vice President, Strategy and Corporate Operations
Julie D. Tracy, Senior Vice President, Chief Communications Officer

Employees: Approx. 1,200 employees worldwide – as of December 2008

Headquarters: ev3 Inc.
9600 54th Avenue North
Plymouth, MN 55442
Phone: (763) 398-7000
Fax: (763) 398-7200

Internet: www.ev3.net

###